The article discusses TIGIT drugs, a class of cancer immunotherapies that have largely failed to deliver on their initial promise. Similar to the disappointing amyloid-beta drugs for Alzheimer's, TIGIT drugs were developed in the wake of the immense success of Keytruda, another immunotherapy. Despite significant investment and hope, TIGIT drugs have not shown clinically meaningful effects, leading to their current status as a cautionary tale in pharmaceutical research. AI
RANK_REASON The article is a commentary on the failure of a class of drugs, drawing parallels to other disappointing drug classes.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
